Abuse-deterrent opioids cross an ethical line
The Commissioner of the Food and Drug Administration, addressing agency staff in May 2017, called the problem of opioid abuse “unquestionably, our greatest immediate challenge.” At the time, the Centers for Disease Control and Prevention had reported 33,000 opioid overdose deaths in 2015, the majority from heroin and fentanyl. Sadly, next month the CDC is expected to report much worse mortality numbers for 2016.
Among the steps the FDA is taking to combat this trend is its policy of encouraging drug makers to develop abuse-deterrent formulations of prescription opioids. The idea is to make it more difficult for opioid abusers to engage in nonmedical use of prescription opioids. In September the FDA announced it will soon issue an updated guidance document to assist manufacturers in developing an expanded spectrum of ADFs including generic versions.
Yet evidence shows that ADFs inflict harm — unintentional and intentional — on nonmedical drug users. By promoting them, the government might be crossing an ethical line, and it wouldn’t be the first time the government has done so when addressing substance use and abuse.
Native American Heritage Day: Diversity and inclusion are Serrano traditions
We must eliminate renewable energy subsidies to ensure reliable, affordable electricity
Secret union negotiations aren’t in the best interest of taxpayers
Jerry Brown pontificates on climate change
When did Thanksgiving become a shopping day?
During alcohol prohibition, ethanol was still permitted for commercial use, to make fuel, dyes, paints and other products, as well as for scientific research. To prevent black market activity, the federal government […]